Hiring in life sciences? Share your open positions with our professional community. Read more Close

Advertisement

Tumor Cell-Free DNA Assay Analytical Performance in 101 Clinical Laboratories Participating in a College of American Pathologists Proficiency Testing Program.

Created on 17 Nov 2026

Authors

Christina M Lockwood, Venkata Yellapantula, Jonathan M Tsai, Rhona J Souers, Patricia Vasalos, Kelly Devereaux, Rondell P Graham, Meera Hameed, Neal Lindeman, Jason D Merker, Mark Routbort, Rena R Xian, Joel T Moncur

Published in

Archives of pathology & laboratory medicine. Oct 05, 2026. Epub Oct 05, 2026.

Abstract

Tumor cell-free DNA (cfDNA) assays are increasingly used for mutation detection in therapy selection and disease monitoring. This study evaluates the laboratory performance in College of American Pathologists (CAP) Molecular Oncology Committee tumor cfDNA proficiency testing (PT) during a 2-year period.
To assess the analytical performance of clinical laboratories offering tumor cfDNA assays using well-characterized PT specimens and compare performance across analytical methods.
This study examined laboratory performance in CAP cfDNA PT programs from 2018 and 2019, with laboratories receiving multiple mailings longitudinally. Testing encompassed 12 specimens targeting 16 clinically significant canonical single-nucleotide variants in 5 oncogenes: EGFR (epidermal growth factor receptor), KRAS (KRAS proto-oncogene, GTPase), BRAF (B-Raf proto-oncogene, serine/threonine kinase), NRAS, (NRAS proto-oncogene, GTPase), and IDH1 (isocitrate dehydrogenase 1). A total of 5088 PT responses from 101 laboratories were analyzed. Results were classified as true positive, false negative, true negative, or false positive, and stratified by next-generation sequencing (NGS) versus non-NGS methods and US Food and Drug Administration-approval status.
Gene-specific sensitivities ranged from 87.1% (176 of 202) to 100.0% (80 of 80), with specificities from 98.7% (1284 of 1301) to 100.0% (827 of 827). For EGFR mutations, which had samples at lower variant allele fractions (VAFs), NGS-based assays demonstrated higher sensitivity than non-NGS methods (95.7% [88 of 92] versus 81.7% [85 of 104]; P = .002). Within the 0.1% to 0.3% VAF range, NGS-based approaches achieved significantly higher sensitivity (96.1% [73 of 76]) than non-NGS methods (78.2% [61 of 78]) (P = .01).
Clinical laboratories achieved high analytical sensitivity and specificity for tumor cfDNA PT across 5 oncogenes. NGS-based assays demonstrated superior analytical performance for EGFR mutation detection at low VAFs, with performance differences most pronounced in the 0.1% to 0.3% VAF range.

PMID:
43042949
Bibliographic data and abstract were imported from PubMed on 17 Nov 2026.

Read full publication at:
Please sign in to see all details.

Advertisement

Stats

  • Community rating n/a 0 votes
  • Reviewers' rating n/a 0 votes
  • Your rating

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

  • Recommendations n/a n/a positive of 0 vote(s)
  • Views 3
  • Comments 0

Recommended by

  • No recommendations yet.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.

Advertisement